

## ASX RELEASE

### Johns Hopkins Hospital Study Data to be presented at USCAP 2018

**Melbourne, Australia, 8 November 2017:** [Sienna Cancer Diagnostics](#), a commercial stage, medical technology company focussed on the development and commercialisation of innovative cancer-related tests, is pleased to announce that an abstract discussing the results of a study performed by researchers at Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018.

Researchers from Johns Hopkins said the study, which commenced in July 2016, is based on results from a cohort of 500 patients undergoing investigation for bladder cancer by urine cytology and/or cystoscopy. Testing for the presence of hTERT in urothelial cells was performed on all 500 patients, and the results correlated with findings of the other tests.

The USCAP annual conference will be held in Vancouver, Canada from March 17 – 23, 2018. USCAP describes the meeting as the largest and most influential meeting of pathologists in the world. It is attended by over 5,000 pathologists from almost 90 countries.

On the acceptance of the abstract, Sienna CEO Matthew Hoskin said “Having the results of a study on Sienna’s IVD test presented at such a well-attended meeting gives it terrific exposure to a large number of physicians who will have the opportunity to familiarise themselves with the test. Johns Hopkins is a renowned research institution that employs researchers who are at the leading edge of their field. The fact that the results of the study will be presented by such a prestigious institution adds credibility to the findings.”

Johns Hopkins Hospital is the teaching hospital and biomedical research facility of the Johns Hopkins School of Medicine, located in Baltimore, Maryland, USA. The hospital is a non-profit academic medical centre, setting healthcare standards in patient care, research, and education.

ENDS.

**For further information, please contact:**

Matthew Hoskin, CEO  
Sienna Cancer Diagnostics  
[mhoskin@siennadiagnostics.com.au](mailto:mhoskin@siennadiagnostics.com.au)  
+61 3 8288 2141

Lauren Nowak  
WE Buchan  
[lnowak@we-buchan.com](mailto:lnowak@we-buchan.com)  
+61 3 8866 1206





### **About Sienna Cancer Diagnostics**

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company with operations in the United States, Europe, and Australia. Sienna's strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The Company has demonstrated the utility of its product with the help of its global clinical partners. Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised as a remarkable biomarker used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna's first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the SCD-A7 reagent can be used for clinical diagnostic purposes by pathology laboratories. Clinical pathology laboratories in those regions may now purchase SCD-A7 for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase. Sienna has made available to pathology laboratories a world-first telomerase-based assay for use on human clinical specimens.

